The Melatonergic System in Mood and Anxiety Disorders and the Role of Agomelatine: Implications for Clinical Practice

The Melatonergic System in Mood and Anxiety Disorders and the Role of Agomelatine: Implications for Clinical Practice

Melatonin exerts its actions through membrane MT1/MT2 melatonin receptors, which belong to the super family of G-protein-coupled receptors consisting of the typical seven transmembrane domains. MT1 and MT2 receptors are expressed in various tissues of the body either as single ones or together. A gr...

Full description

Bibliographic Details
Main Authors:	Domenico De Berardis, Stefano Marini, Michele Fornaro, Venkataramanujam Srinivasan, Felice Iasevoli, Carmine Tomasetti, Alessandro Valchera, Giampaolo Perna, Maria-Antonia Quera-Salva, Giovanni Martinotti, Massimo di Giannantonio
Format:	Article
Language:	English
Published:	MDPI AG 2013-06-01
Series:	International Journal of Molecular Sciences
Subjects:	melatonin melatonergic receptors serotonin dopamine noradrenaline agomelatine major depression anxiety
Online Access:	http://www.mdpi.com/1422-0067/14/6/12458

Similar Items

Agomelatine beyond Borders: Current Evidences of Its Efficacy in Disorders Other than Major Depression
by: Domenico De Berardis, et al.
Published: (2015-01-01)

Sleep Disorders in Shift Workers in the Emergency Department and Efficacy of Melatonin
by: Mücahit Emet, et al.
Published: (2016-03-01)

A Comparative Study of Efficacy and Safety of Agomelatine and Escitalopram in Major Depressive Disorder
by: Ravi Babu. Komaram, et al.
Published: (2015-06-01)

Agomelatine – pharmacological properties and use in psychiatric practice
by: Marcin Siwek, et al.
Published: (2019-06-01)

Integrative Pan-Cancer Analysis Reveals Decreased Melatonergic Gene Expression in Carcinogenesis and RORA as a Prognostic Marker for Hepatocellular Carcinoma
by: Yi Zou, et al.
Published: (2021-03-01)

Assessment of the innovative quality of agomelatine through the Innovation Assessment Algorithm
by: Liliana Civalleri, et al.
Published: (2012-09-01)

Novel Conformationally Constrained Analogues of Agomelatine as New Melatoninergic Ligands
by: Marouan Rami, et al.
Published: (2012-12-01)

UV SPECTROPHOTOMETRIC METHOD FOR QUANTITATIVE DETERMINATION OF AGOMELATINE IN COATED TABLETS
by: Fábio de Souza Barbosa, et al.
Published: (2017-12-01)

Suspected Agomelatine-induced restless legs syndrome: a case report
by: Mustafa Abdul Karim, et al.
Published: (2021-04-01)

Implementation of a reference-scaled average bioequivalence approach for highly variable generic drug products of agomelatine in Chinese subjects
by: Fang Tang, et al.
Published: (2016-01-01)

Agomelatine in the treatment of mild-to-moderate depression in patients with cardiovascular disease: results of the national multicenter observational study PULSE
by: Medvedev VE
Published: (2017-04-01)

Selektif serotonin geri alım inhibitörünün neden olduğu ve agomelatin ile düzelen akut açı kapanması glokomu
by: Mahmut Onur KARAYTUĞ, et al.
Published: (2019-12-01)

Optimization and improvement of the synthesis method of agomelatine
by: Lei LIU, et al.
Published: (2018-02-01)

Agomelatine versus paroxetine in treating depressive and anxiety symptoms in patients with chronic kidney disease
by: Chen JW, et al.
Published: (2018-02-01)

Parallel Changes in Mood and Melatonin Rhythm Following an Adjunctive Multimodal Chronobiological Intervention With Agomelatine in People With Depression: A Proof of Concept Open Label Study
by: Rebecca Robillard, et al.
Published: (2018-12-01)

Agomelatine Attenuates Isoflurane-Induced Inflammation and Damage in Brain Endothelial Cells
by: Cheng F, et al.
Published: (2020-12-01)

AGOMELATINE IN THE TREATMENT OF ANXIETY AND DEPRESSIVE DISORDERS IN PATIENTS WITH ISCHEMIC HEART DISEASE
by: N. Yu. Shimohina, et al.
Published: (2017-03-01)

Agomelatine reduces circulating triacylglycerides and hepatic steatosis in fructose-treated rats
by: Vanessa Barbosa Veronesi, et al.
Published: (2021-09-01)

Differentiated approach and indications for optimization of agomelatine therapy for endogenous depression
by: L. I. Abramova, et al.
Published: (2019-06-01)

EVALUATION OF MENTAL STATUS AND ITS CORRECTION AGOMELATINE IN PATIENTS WITH ACUTE CORONARY SYNDROME
by: T. M. Poponina, et al.
Published: (2013-12-01)

Agomelatine protects against neuronal damage without preventing epileptogenesis in the kainate model of temporal lobe epilepsy
by: Jana Tchekalarova, et al.
Published: (2017-08-01)

Sub-Acute Oral Toxicity of a Novel Derivative of Agomelatine in Rats in a Sex-Dependent Manner
by: Qiushi Yang, et al.
Published: (2019-03-01)

Inhibitory effect of celecoxib on agomelatine metabolism in vitro and in vivo
by: He JY, et al.
Published: (2018-03-01)

The effect of agomelatine and melatonin on sleep-related eating: a case report
by: Angela Alexandra Zapp, et al.
Published: (2017-09-01)

Comparison of the effects of sertraline and agomelatine on sleep quality, sexual functioning and metabolic parameters in patients with major depressive disorder
by: Anıl Talas, et al.
Published: (2019-07-01)

Agomelatine, A Potential Multi-Target Treatment Alternative for Insomnia, Depression, and Osteoporosis in Postmenopausal Women: A Hypothetical Model
by: Ahmet Yardimci, et al.
Published: (2021-06-01)

Transdermal agomelatine microemulsion gel: pyramidal screening, statistical optimization and in vivo bioavailability
by: Mayada Said, et al.
Published: (2017-01-01)

Agomelatine is superior to melatonin in pain suppression: An experimental study
by: Ali Okan Yucel, et al.
Published: (2020-01-01)

Agomelatine versus fluoxetine in glycemic control and treating depressive and anxiety symptoms in type 2 diabetes mellitus subjects: a single-blind randomized controlled trial
by: Che T, et al.
Published: (2018-06-01)

Drug use evaluation: A two‐year retrospective review of the effectiveness and tolerability of agomelatine versus mirtazapine in patients with depressive disorder
by: Shek Ming Leung
Published: (2021-08-01)

Oral bioavailability enhancement of agomelatine by loading into nanostructured lipid carriers: Peyer’s patch targeting approach
by: Prajapati JB, et al.
Published: (2018-03-01)

Approaches to therapy for depressions in neurology: prospects for the use of agomelatine
by: D. V. Romanov, et al.
Published: (2018-12-01)

Alopecia associated with agomelatine use: a case report
by: Ibrahim Gundogmus, et al.
Published: (2018-01-01)

Oxymatrine ameliorates agomelatine-induced hepatocyte injury through promoting proteasome-mediated CHOP degradation
by: Yina Jia, et al.
Published: (2019-06-01)

Melatonin receptor stimulation by agomelatine prevents Aβ-induced tau phosphorylation and oxidative damage in PC12 cells
by: Yao K, et al.
Published: (2019-01-01)

Low-Frequency versus High-Frequency Ultrasound-Mediated Transdermal Delivery of Agomelatine-Loaded Invasomes: Development, Optimization and in-vivo Pharmacokinetic Assessment
by: Tawfik MA, et al.
Published: (2020-11-01)

Does celecoxib inhibit agomelatine metabolism via CYP2C9 or CYP1A2?
by: Yasar U
Published: (2018-07-01)

Qbd based analytical method development and validation for the separation and quantification of agomelatine and its impurities in solid oral dosage forms using hplc
by: Anna, V.R, et al.
Published: (2021)

DRUG REPOSITIONING: Revisiting the basic psychopharmacological mechanism of action for agomelatine and where it should be classified?
by: Olumuyiwa John Fasipe, et al.
Published: (2019-01-01)

Chronic agomelatine treatment prevents comorbid depression in the post-status epilepticus model of acquired epilepsy through suppression of inflammatory signaling
by: Jana Tchekalarova, et al.
Published: (2018-07-01)

Cannot write session to /tmp/vufind_sessions/sess_4t8fcijq94rc611ph4dmvk70jn